Martin E Gleave
University of British Columbia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martin E Gleave as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04812366 · Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerUniversity of British Columbia · recruiting · Prostate Cancer · study chair
- N/ANCT02572804 · Comparing Rectus Sheath Catheter to Epidural Post CystectomyVancouver Coastal Health · unknown · Bladder Cancer, Postoperative Pain · principal investigator
- N/ANCT00999427 · Prostate Biopsy AntisepsisUniversity of British Columbia · completed · Infective Complications Post-transrectal Prostate Biopsy · study chair
- N/ANCT00756665 · Prostate Active Surveillance StudyUniversity of Washington · recruiting · Prostatic Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:31 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.Cancer Discov · 2018442 citationsRCR 14.2
- 413 citationsRCR 9.0
- Active surveillance of small renal masses: progression patterns of early stage kidney cancer.Eur Urol · 2011396 citationsRCR 12.4
- 297 citationsRCR 10.2
- 251 citationsRCR 5.4
- Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.N Engl J Med · 1998245 citationsRCR 4.5
- Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.Urology · 1995226 citationsRCR 7.2
- A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.J Natl Cancer Inst · 2005224 citationsRCR 4.4
- Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.J Clin Oncol · 2010188 citationsRCR 4.4
- A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.Clin Cancer Res · 2001179 citationsRCR 3.4